Relmada Therapeutics Registers Over 33 Million Shares for Resale Following $160M Private Placement

summarizeSummary

This S-3 filing registers 33.68 million shares of common stock for resale by selling stockholders, stemming from a $160 million private placement that closed on March 11, 2026. While the company will not receive proceeds from these resales, this registration fulfills a prior agreement and makes these shares freely tradable. This event follows the company's recent announcement of securing $254 million in new financing to resolve its going concern status and advance its clinical pipeline. The registration of such a large block of shares (representing over 32% of outstanding shares) creates a significant market overhang, potentially impacting the stock price as investors gain the ability to sell.

check_boxKey Events

• Resale Registration Filed

  Relmada Therapeutics filed an S-3 registration statement for the resale of up to 33,685,096 shares of common stock by selling stockholders.

• Follows $160 Million Private Placement

  These shares were issued in a private placement that closed on March 11, 2026, raising approximately $160 million for the company. The private placement shares were sold at $4.75 per share for common stock and $4.749 for pre-funded warrants.

• Significant Market Overhang

  The registered shares represent approximately 32.11% of the company's outstanding common stock, creating a substantial overhang as these shares become freely tradable.

• No Direct Proceeds to Company

  The company will not receive any proceeds from the sale of shares by the selling stockholders, as this filing is solely for their resale.

auto_awesomeAnalysis

This S-3 filing registers 33.68 million shares of common stock for resale by selling stockholders, stemming from a $160 million private placement that closed on March 11, 2026. While the company will not receive proceeds from these resales, this registration fulfills a prior agreement and makes these shares freely tradable. This event follows the company's recent announcement of securing $254 million in new financing to resolve its going concern status and advance its clinical pipeline. The registration of such a large block of shares (representing over 32% of outstanding shares) creates a significant market overhang, potentially impacting the stock price as investors gain the ability to sell.